Anavex Life Sciences Corp (AVXL)

[georgejjl]

This is interesting:

Falls reported in the Phase 2b/3 trial 7% for for those on blarcamesine are about 30% reduced from 9.9% for those on placebo.

One might say that blarcamesine appears to reduce the incidents of falls by 30% compared to placebo.

Similar to the following:

Blarcamesine was reported to slow decline CDR-SB by 27 percent.

Good luck and GOD bless,